Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths, CEM; BADBIR Study Group
Read publication: BJD
Related
Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational ...
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for pa...
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the Br...
0 Comments